Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alprazolam inhalation - Engage Therapeutics

Next Previous
Drug Profile

Alprazolam inhalation - Engage Therapeutics

Alternative Names: AZ-002; FNP-002; Staccato® alprazolam; STAP-001; UCB 7538

Latest Information Update: 15 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexza Pharmaceuticals
  • Developer Alexza Pharmaceuticals; Engage Therapeutics; UCB Biopharma
  • Class Antiepileptic drugs; Anxiolytics; Azoles; Benzodiazepines; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Epilepsy
  • No development reported Asthma
  • Discontinued Panic disorder

Most Recent Events

  • 11 Dec 2025 Lee's Pharmaceutical acquires Staccato® One Breath Technology® platform and assets including intellectual property, know-how, trademarks, product pipeline, equipment, products and access to GMP facility from Alexza Pharmaceuticals
  • 13 Jun 2025 UCB Pharma plans a phase I trial for Healthy volunteers (In adults) in July 2025 (NCT07020988)
  • 12 Jun 2025 UCB Biopharma SRL initiates phase-I safety trial (In volunteers) in USA (Inhalation) (NCT07020988)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top